The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease

BÜHLMANN fCAL® ELISA Citation

Zhulina, Y. et al., 2016, The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease, Aliment Pharmacol Ther.  PMID: 27402063 DOI: 10.1111/apt.13731

Highlight from this Publication

“Our data suggest that longitudinal monitoring of faecal calprotectin is informative in predicting relapse in IBD.“

BÜHLMANN fCAL® ELISA is FDA 510(k) cleared For in vitro Diagnostic Use.

Health Canada License: 80726